PDCD1 and Autoimmunity: Previous studies in recent years assumed that these patients with higher levels of autoimmunity may benefit from anti-cancer treatment via autoimmune pathways because they are more susceptible to autoimmunity, which is supported by numerous studies indicating a positive correlation between irAEs and improved response and survival rates in patients treated with anti–PD-1 (39–44).